Evaluation of the effects of risedronate on hepatic microsomal drug metabolizing enzyme activities following administration to rats for 14 days: Lack of an induction response

Drug and Chemical Toxicology

Volumn 21, Issue 3, 1998, Pages 291-303

  Smith, Bill J ^a,b   Hu, Joanna K ^a   Schwecke, William P ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME METABOLISM; FOOD INTAKE; INTRAGASTRIC DRUG ADMINISTRATION; LIVER MICROSOME; NONHUMAN; PROTEIN CONTENT; RAT; ULTRACENTRIFUGATION;

ANIMALIA;

EID: 0031857382     PISSN: 01480545     EISSN: None     Source Type: Journal    
DOI: 10.3109/01480549809002206     Document Type: Article

References (15)

1. Sipes I.G. and Gandolfi A.J., Biotransformation of toxicants, Toxicology. The Basic Science of Poisons. Fourth Edition, 88-126, 1991.
2. Sietsema, W.K., Ebetino, F.H., Salvagano, A.M. and Bevan, J.A., Antiresorptive dose response relationships across three generations of bisphosphonates, Drugs Exptl. Clin. Res., 15: 389-396, 1989.
3. Hosking, D.J., Eusebio, M.S., and Chines, A.A., Paget's disease of bone: Reduction of disease activity with oral risedronate, Bone, (in press).
4. Chines, A., Bekker, P., Clarke, P. and Hosking, D., Reduction of bone pain and alkaline phosphatase in patients with severe Paget's disease following treatment with risedronate, J. Bone Miner. Res., 11 (suppl. 1): S371, 1996.
5. Mortensen, L., Charles, P., Bekker, P.J., Digennaro, J. and Johnston Jr., C.C., Risedronate increases bone mass in an early postmenopausal population: 2 years of treatment plus 1 year of follow-up, J. Clin. Gastroenterol. Metabol., (in press).
6. Guengerich F.P., Analysis and characterization of enzymes, Principles and Methods of Toxicology, 785-786, 1989.
7. Omura, T. and Sato, R., The carbon monoxide-binding pigment of liver microsomes. I Evidence for its hemoprotein nature, J. Biol. Chem., 239: 2370-2378, 1964.
8. Mazel, P., Experiments illustrating drug metabolism in vitro, Fundamentals of Drug Metabolism and Drug Disposition, 546-582, 1971.
9. Nash, T., The colorimetric estimation of formaldehyde by means of the Hantzsch reaction, Biochem. J., 55: 416-421, 1953.
10. Aitio, A., A simple and sensitive assay of 7-ethoxycoumarin deethylation, Anal. Biochem., 85: 488-491, 1978.
11. Martin, S.T. and Black, S.D., Detergent effects in rabbit liver microsomal UDP glucuronosyltransferase studied by means of a continuous spectrophotometric assay with p-nitrophenol, Biochem. Biophys. Res Commun., 200: 1093-1098, 1994.
12. Howard, M.O., Schwartz, L.W., Newton, J.F., Qualls, C.W., Yodis, L.P. and Ventre, J.R., Comparative biochemical and morphometric changes associated with induction of the hepatic mixed function oxidase system in the rat, Toxicol. Pathol., 19: 115-122, 1991.
13. Guengerich, F.P., Dannan, G.A., Wright, S.T., Martin, M.V. and Kaminsky, L.S., Purification and characterization of liver microsomal cytochromes P-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or β-naphthoflavone, Biochemistry, 21: 6019-6030, 1982.
14. Watkins, J.B., Gregus, Z., Thompson, T.N. and Klaassen, C.D., Induction studies on the functional heterogeneity of rat liver UDP-glucuronosyltransferases, Toxicol. Appl. Pharmacol., 64: 439-446, 1982.
15. Papac, D.I. and Franklin, M.R., N-Benzylimidazole, a high magnitude inducer of rat hepatic cytochrome P-450 exhibiting both polycyclic aromatic hydrocarbon- and phenobarbital-type induction of phase I and phase II drug-metabolizing enzymes, Drug Metab. Dispos., 16: 259-264, 1988.